Getting Tests Where They’re Needed Most
Access Bio was founded on the basic principle of cherishing life and health for all people. The company has emerged as a leader in the diagnosis of infectious diseases. Although it provides a comprehensive portfolio, Access Bio is known for its work against malaria, HIV, HPV, and now, COVID-19.
Core to fulfilling this mission is Access Bio’s unique structure that allows them to be both nimble and responsive to emerging threats and trends but gives them the size, strength, and reach necessary to distribute fairly-priced products all over the world. Access Bio is headquartered in the United States, with production facilities strategically located in New Jersey, Ethiopia, and South Korea. Access Bio can produce more than 170 million rapid diagnostic tests a year, and distributes products to more than 120 different countries.
At the beginning of COVID-19 pandemic, Access Bio mobilized to produce the high-quality, highly sensitive tests required to help stop the spread. It has developed PCR, antigen, and antibody testing, to better assess not only active infections but past exposure to SARS-CoV-2. Access Bio quickly received approval to distribute the products throughout Asia, and, in March 2020, Access Bio’s PCR test was CE-marked. On July 21, 2020, the company announced that its CareStart™ COVID-19 MDx RT-PCR test was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration.
The announcement comes at a critical time: the nation lost valuable time in developing effective testing options and had been burdened by sub-standard or defective tests. Access Bio has long been a trusted partner to organizations that include UNICEF and the World Health Organization. Together with the fact that the company can domestically produce more than 1.2 million tests a day, there is reason for hope that the nation may be able to test at the volume necessary to aid containment efforts.